NEW
YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Kyverna
Therapeutics, Inc. (NASDAQ: KYTX).
Shareholders who purchased shares of KYTX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=117784&from=4
CLASS PERIOD: This lawsuit is on behalf of all those who
purchased or otherwise acquired Kyverna common stock pursuant
and/or traceable to the Company's offering documents issued in
connection with its February 2024
initial public offering.
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i) the
strategy to best accomplish the IPO; (ii) the terms of the IPO,
including the price at which Kyverna's common stock would be sold;
(iii) the language to be used in the Offering Documents; (iv) what
disclosures about Kyverna would be made in the Offering Documents;
and (v) what responses would be made to the SEC in connection with
its review of the Offering Documents. As a result of those constant
contacts and communications between the underwriter defendants'
representatives and Kyverna's management, directors, and lawyers,
at a minimum, the underwriterd defendants should have known of
Kyverna's undisclosed then-existing problems and plans, and the
Offering Document's materially inaccurate, misleading, and
incomplete statements and omissions, as detailed herein.
DEADLINE: February 7, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=117784&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of KYTX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is February 7, 2025. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lost-money-on-kyverna-therapeutics-inckytx-join-class-action-suit-seeking-recovery--contact-the-gross-law-firm-302337798.html
SOURCE The Gross Law Firm